UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Journal of thoracic oncology, 2020-08, Vol.15 (8), p.1281-1297

2020

Volltextzugriff (PDF)

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Cancer treatment reviews, 2014-09, Vol.40 (8), p.917-926

2014

Volltextzugriff (PDF)

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.1396-1403

2015

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Volltextzugriff (PDF)

ALK inhibitors in the treatment of advanced NSCLC

Cancer treatment reviews, 2014-03, Vol.40 (2), p.300-306

2014

Volltextzugriff (PDF)

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

Clinical cancer research, 2004-06, Vol.10 (12), p.4276s-4280s

ADJEI, Alex A

2004

Volltextzugriff (PDF)

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004424

2022

Volltextzugriff (PDF)

Advances in Chemotherapy of Non-small Cell Lung Cancer

Chest, 2006-10, Vol.130 (4), p.1211-1219

2006

Volltextzugriff (PDF)

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Journal of clinical oncology, 2004-11, Vol.22 (22), p.4456-4462

2004

Volltextzugriff (PDF)

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

Journal of clinical oncology, 2010-02, Vol.28 (4), p.614-619

2010

Volltextzugriff (PDF)

Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2003-05, Vol.21 (9), p.1760-1766

2003

Volltextzugriff (PDF)

Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

Clinical cancer research, 2007-05, Vol.13 (9), p.2684-2691

2007

Volltextzugriff (PDF)

Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer

Cancer research and treatment, 2022-04, Vol.54 (2), p.315-329

2022

Volltextzugriff (PDF)

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1610-1623

2017

Volltextzugriff (PDF)

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study

Journal of thoracic oncology, 2010-09, Vol.5 (9), p.1346-1353

2010

Volltextzugriff (PDF)

New strategies to develop new medications for lung cancer and metastasis

Cancer and metastasis reviews, 2015-06, Vol.34 (2), p.265-275

2015

Volltextzugriff (PDF)

Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5929-5937

2005

Volltextzugriff (PDF)

Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?

Nature reviews. Clinical oncology, 2015-01, Vol.12 (1), p.8-10

2015

Volltextzugriff (PDF)

Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020

JAMA network open, 2022-01, Vol.5 (1), p.e2144923-e2144923

2022

Volltextzugriff (PDF)

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

European journal of cancer (1990), 2017-11, Vol.86, p.186-196

2017

Volltextzugriff (PDF)

K-ras as a Target for Lung Cancer Therapy

Journal of thoracic oncology, 2008-06, Vol.3 (6), p.S160-S163

Adjei, Alex A.

2008

Volltextzugriff (PDF)

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents

Clinical cancer research, 2006-07, Vol.12 (14 Pt 2), p.4365s-4371s

2006

Volltextzugriff (PDF)

Thoracoscopic Organ Suffusion for Regional Lung Chemotherapy (Preliminary Results)

The Annals of thoracic surgery, 2009-08, Vol.88 (2), p.385-391

2009

Volltextzugriff (PDF)

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

Journal of thoracic oncology, 2021-06, Vol.16 (6), p.960-967

2021

Volltextzugriff (PDF)

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer

Anti-cancer drugs, 2013-11, Vol.24 (10), p.1079-1083

2013

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Aktive Filter

ThemaCarcinoma, Non-Small-Cell Lung - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(61)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

Humans
(61)
Lung Neoplasms - Drug Therapy
(60)
Life Sciences & Biomedicine
(54)
Science & Technology
(54)
Oncology
(52)
Aged
(31)
Male
(31)
Female
(30)
Middle Aged
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Respiratory System
(20)
Lung Neoplasms - Pathology
(18)
Pneumology
(16)
Tumors
(16)
Tumors Of The Respiratory System And Mediastinum
(16)
Aged, 80 And Over
(15)
Adult
(14)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

ALK inhibitors in the treatment of advanced NSCLC

Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Advances in Chemotherapy of Non-small Cell Lung Cancer

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer: A North Central Cancer Treatment Group-Based Exploratory Study

New strategies to develop new medications for lung cancer and metastasis

Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer

Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?

Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

K-ras as a Target for Lung Cancer Therapy

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents

Thoracoscopic Organ Suffusion for Regional Lung Chemotherapy (Preliminary Results)

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer

Aktive Filter

Suchergebnisse filtern